ClinicalTrials.gg
RecruitingNCT07914556Updated Nov 3, 2026

Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers

A Phase 1 interventional study of 6MW5311 in AML, Multiple Myeloma and CMML, sponsored by Mabwell (Shanghai) Bioscience Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 3, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
122
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.

Planned enrollment
86th of 406
122 · median 40
Started
2026
with 53 others
Phase 1
151 of 448
73 open now
Primary completion
2029-12
later than 256 of 274 live
Registered
444th of 448
by date

Among the 448 studies in Multiple Myeloma with a site in China, this one is the 86th largest by planned enrollment of the 406 interventional ones that give a count, is one of 54 that started in 2026, is one of 151 in phase 1, reaches primary completion later than 256 of the 274 other live ones, and was the 444th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:

232 more — sign in →

All 238 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Multiple Myeloma with a site in China, or all of them as a file.
02

Study summary

To assess safety and tolerability at increasing dose levels of 6MW5311 in successive cohorts of participants with MM, AML and CMML in order to estimate the maximum tolerated dose (MTD) and select the recommended Phase 2 dose (RP2D) or the recommended expansion dose (RED).

Read the detailed description

This is a 2-part, open-label, multicenter, First-in-Human Phase 1 clinical trial consisting of dose escalation (Part 1) and dose expansion (Part 2). Part 1 will evaluate the safety and tolerability, immunogenicity, PK/PD, biomarker, and preliminary clinical activities of 6MW5311. Part 2 will select appropriate dose(s) for expansion based on preliminary efficacy, safety, immunogenicity, PK/PD, and biomarkers data from Part 1, and will further assess the safety, PK, biomarker, and efficacy of 6MW5311. Upon completion of the Phase 1 clinical trial and findings from non-clinical studies, the recommended expansion dose (RED) or recommended Phase 2 dose (RP2D) of 6MW5311 in patients with hematological malignancies will be determined.

03

Conditions studied

  • AML
  • Multiple Myeloma
  • CMML

Browse trials for

Keywords

  • LILRB4
  • CD3
  • TCE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older at the time of signing the form; male or female.
  2. (ECOG) performance status of 0 or 1 for the dose-escalation part, or 0 to 2 for the dose-expansion part.
  3. greater than 3 months.
  4. Multiple myeloma (MM): and/or cytologically confirmed MM per International Myeloma Working Group (IMWG) 2016 criteria, with at least 3 prior lines of MM therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

    • Chronic myelomonocytic leukemia (CMML): morphologically confirmed by bone marrow examination per World Health Organization (WHO) 2016 classification, with disease or failure of prior therapy.
    • Acute myeloid leukemia (AML; dose-expansion part only): morphologically confirmed acute myelomonocytic leukemia or acute monocytic leukemia per WHO 2016 classification, meeting the protocol definition of relapsed or refractory AML.
  5. MM only: at screening.
  6. Adequate hematologic function at screening:
  7. Able to understand and comply with the protocol requirements, willing to participate in the clinical study, and able to provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  • 1. AML and CMML only: any other anticancer therapy within 2 weeks before the first dose of study drug.

MM only: prior anticancer therapy within the following intervals before the first dose of study drug:

  • small-molecule targeted therapy within 4 weeks or 5 half-lives, whichever is shorter;
  • antibody therapy within 3 weeks;
  • cytotoxic chemotherapy, proteasome inhibitor therapy, or traditional Chinese medicine (including Chinese patent medicine) with an anticancer indication within 2 weeks;
  • immunomodulatory agent within 1 week;
  • chimeric antigen receptor T-cell (CAR-T) therapy within 3 months;
  • radiotherapy within 1 week. 2. Receipt of any other drug within 4 weeks before the first dose of study drug.

    3. Prior stem cell transplant; or autologous stem cell transplant within 3 months before the first dose of study drug.

    4. Planned stem cell transplant during the study. 5. Prior treatment with a LILRB4-targeted therapy.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
122 participants (estimated)

Study arms

  • Experimental
    Part 1 - Dose Escalation (6MW5311)

    A modified 3+3 design with accelerated titration will be used to evaluate planned dose levels.

    Biological: 6MW5311

  • Experimental
    Part 2 - Dose Expansion (6MW5311)

    Participants with chronic myelomonocytic leukemia (CMML), multiple myeloma (MM), or relapsed or refractory acute myeloid leukemia (AML; acute myelomonocytic or monocytic subtypes) will receive 6MW5311 at the dose level(s) selected by the Safety Review Committee from Part 1.

    Biological: 6MW5311

Interventions

  • Biological6MW5311

    A bispecific T cell engager (TCE) antibody: bivalent binding to LILRB4 on tumor cells and monovalent binding to CD3 on T cells.

06

What researchers measure

Primary outcomes

  1. Number of participants with dose-limiting toxicities (DLTs)

    DLTs are adverse events considered related to 6MW5311 (definitely, probably, or possibly related) that occur during the dose-limiting toxicity observation period (first 28 days after the first dose of Cycle 1). DLTs are defined per the protocol and graded per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 6.0.

    Time frame: From the first dose of Cycle 1 through Day 28 of Cycle 1 (each cycle is 28 days)

  2. Number of participants with treatment-emergent adverse events (TEAEs)

    TEAEs will be graded per NCI CTCAE version 6.0 and coded by system organ class and preferred term.

    Time frame: From first dose through 28 days after the last dose, an average of 1 year

Secondary outcomes

  1. Overall response rate (ORR)

    ORR is the proportion of participants with a confirmed response. For multiple myeloma: the sum of confirmed stringent complete response, complete response, very good partial response, and partial response per International Myeloma Working Group (IMWG) 2016 criteria. For acute myeloid leukemia: the sum of confirmed complete response, complete remission with incomplete hematologic recovery, complete remission with partial hematologic recovery, morphologic leukemia-free state, and partial response per European LeukemiaNet (ELN) 2022 criteria. For chronic myelomonocytic leukemia: the sum of confirmed complete response, marrow response, partial response, and clinical benefit per the international MDS/MPN working group criteria.

    Time frame: From first dose through end of treatment, an average of 1 year

  2. Maximum observed serum concentration (Cmax) of 6MW5311

    Cmax is the maximum observed serum concentration of 6MW5311, read directly from the individual serum concentration-time profile after intravenous infusion.

    Time frame: Through study completion, an average of 1 year

  3. Area under the serum concentration-time curve (AUC) of 6MW5311

    Time frame: Through study completion, an average of 1 year

  4. Time to maximum observed serum concentration (Tmax) of 6MW5311

    Time frame: Through study completion, an average of 1 year

  5. Terminal elimination half-life (t1/2) of 6MW5311

    Time frame: Through study completion, an average of 1 year

  6. Systemic clearance (CL) of 6MW5311

    Time frame: Through study completion, an average of 1 year

  7. Volume of distribution (V) of 6MW5311

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Dec 2029, 39 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 39 months is close to that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2026
First posted
Nov 3, 2026
StartActual
Sep 16, 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07914556
Responsible party
Sponsor
First posted
Nov 3, 2026
Start date
Sep 16, 2026
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 3, 2026

Study contacts

Jiangjiang Lv
Contact
jiangjiang.lv@mabwell.com
+86-021-58585793

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion